Table 2.

Model utility inputs

Health state	Base case: Woehl et al. (2008) [28]	Vedolizumab IV trial data (GEMINI 1) [8]
Clinical remission	0.87	0.86
Clinical response	0.76	0.80
Active UC	0.41	0.67
Surgery	0.66a	0.67
Post-surgery remission	0.71	0.68
Post-surgery complications	0.66a	0.49

AEs	Utility decrements associated with AEs
	Disutility	Duration, weeks
Serious infection	− 0.520	10
Upper respiratory tract infection	− 0.550	10
Tuberculosis	− 0.550	10
Malignancies	− 0.195	10
Acute infusion-related AE	− 0.110	10
Injection-site reaction	− 0.030	10
Herpes zoster	− 0.190	10
Myocardial infarction	− 0.125	10
Stroke	− 0.139	10

AE adverse event, IV intravenous, SC subcutaneous, UC ulcerative colitis

^aCalculated as the weighted average of the utility score for surgery used in the cost-effectiveness analysis of infliximab IV, adalimumab SC, and golimumab SC by the National Institute of Health and Care Excellence Assessment Group (0.41) during 8 weeks and the utility score for post-surgery remission (0.71), taken as the average from Archer et al. (2016) [14] and Woehl et al. (2008) [28] for the remainder of the year (i.e., 44 weeks): 0.66 = 0.41 × (8 ⁄ 52) + 0.71 × (44 ⁄ 52)